CMTA strengthens its role as the leading force in comprehensive CMT research, forging a strategic alliance with the Inherited Neuropathy Consortium.
With a $1.2 million annual funding commitment, this partnership positions CMTA as the partner of choice for CMT research and for pharmaceutical companies involved in drug development and clinical trials. INC is a collaborative network of CMT investigators from multiple academic medical centers who currently follow over 8,300 individuals with CMT. Since its inception in 2009, INC has published over 300 manuscripts defining the natural history of multiple CMT subtypes and developing the clinical outcome measures and biomarkers that allow investigators to perform these natural history studies and make the subtypes “Clinical Trial Ready.” INC has identified thirty new genes that cause CMT to date and trained more than twenty outstanding young investigators devoting their careers to CMT research.
CMTA and INC are accelerating progress from the lab to the clinic, advancing trials and treatments that offer hope to the CMT community.
This strategic alliance strengthens CMTA’s longstanding support for INC, rooted in a shared dedication to advancing CMT research on the path to a cure. With NIH funding for INC concluding in 2024 after 15 years by an NIH rule, CMTA’s investment will support biomarkers, clinical outcomes, natural history studies, and other critical tools for clinical trial readiness. This funding also enables genetic testing, new gene discovery, and the training of future CMT researchers, creating tools that pharmaceutical partners rely on to bring innovative medicines to market.
